VSL#3 active

Phase 2Small molecule

NNottingham University Hospitals NHS Trust

VSL#3 active is one of 35 small molecule programs targeting Peritonitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PeritonitisActive, not recruiting

PeritonitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Peritonitis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

3 2

Doribax

Shionogi

Approved

—3

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 4

Experimental

Biogen

Approved

2 5

Eraxis

VVicuron Pharmaceuticals

Approved

—6

Tygacil

PPrism Pharmaceuticals

Approved

—7

Chibroxin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

7 8

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Approved

2 9

Xifaxan

SSalix

Phase 3

5 10

Ancef

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peritonitis1 trial

VSL#3 and Spontaneous Bacterial Peritonitis

Terminated·NNottingham University Hospitals NHS Trust·Phase 2·NCT01701297·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VSL#3 active. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VSL#3 active compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VSL#3 active. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nottingham University Hospitals NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNottingham University Hospitals NHS Trust

VSL#3 active

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peritonitis1 trial

References

Drug Info

Quick Facts

Related News